2018

1. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety

   Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2395-2404

2. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

   The Lancet Oncology, Vol. 19, Núm. 11, pp. 1530-1542